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Perfluorinated chemicals, which have been 
manufactured for > 50 years, have been used 
in a wide range of industrial and consumer 
products. Perfluorooctane sulfonate (PFOS) 
and perfluorooctanoate (PFOA), which are 
representative of perfluorinated chemicals, have 
recently been found to be widespread contami-
nants in the environment, wildlife, and humans 
(Butenhoff et al. 2006; Key et al. 1997; Lau 
et al. 2007; Renner 2001). The worldwide dis-
tribution of PFOS and PFOA is recognized as 
a severe problem because of their resistance to 
further degradation in the environment.
PFOS and PFOA contamination in 
human blood has been reported in various 
countries (Butenhoff et al. 2006; Calafat 
et al. 2007; Harada et al. 2007; Kannan et al. 
2004; Lau et al. 2007; Midasch et al. 2006). 
Maternal serum PFOS and PFOA levels 
measured in our previous study (Inoue et al. 
2004a) were relatively low compared with 
most levels in previous reports (Butenhoff 
et al. 2006; Calafat et al. 2007; Harada et al. 
2007; Kannan et al. 2004; Lau et al. 2007; 
Midasch et al. 2006).
Exposure of pregnant rats and mice to 
PFOS led to a reduction in birth weight 
(Grasty et al. 2003, 2005; Lau et al. 2003; 
Luebker et al. 2005a, 2005b; Thibodeaux 
et al. 2003), and a similar result was obtained 
when pregnant rats and mice were exposed to 
PFOA (Abbott et al. 2007; Butenhoff et al. 
2004; Lau et al. 2006; Wolf et al. 2007). 
Interference of lipid metabolism (Kennedy 
et al. 2004; Loveless et al. 2006; Xie et al. 
2003) and alterations in thyroid hormone 
homeostasis (Lau et al. 2003; Luebker et al. 
2005b; Martin et al. 2007; Thibodeaux et al. 
2003) have been suggested as possible mecha-
nisms of fetal growth restriction. Currently, 
however, the mechanism behind any corre-
lation between PFOS and PFOA and fetal 
growth restriction is not clearly understood.
Human studies have shown no substan-
tial changes in hematologic, lipid, hepatic, 
thyroid, or urinary characteristics in popula-
tions exposed occupationally to perfluorinated 
chemicals (Olsen et al. 1999, 2003). PFOS 
and PFOA were detected in nearly 100% of 
umbilical cord sera in 299 samples (Apelberg 
et al. 2007a), indicating that human fetuses 
are exposed to these chemicals. Our previ-
ous study and another study have shown the 
placental permeability of PFOS and PFOA 
(Inoue et al. 2004a; Midasch et al. 2007). 
Because fetuses might be more vulnerable than 
adults to the potential harmful effects of chem-
icals, exposure assessment studies for perfluori-
nated chemicals in human fetuses are urgently 
needed. One occupational study found no 
correlation between high occupational expo-
sure to PFOS before the end of pregnancy 
and maternally reported birth weight among 
439 singleton live births (Grice et al. 2007). 
Meanwhile, two reports investigated the cor-
relations between prenatal nonoccupational 
PFOS and PFOA exposure and reduced fetal 
growth. One study showed a correlation 
between PFOS and PFOA levels in cord serum 
and reduced values for birth weight, ponderal 
index, and head circumference among 293 
women and their infants. The median con-
centration for PFOA was 1.6 ng/mL and for 
PFOS was 5 ng/mL (Apelberg et al. 2007b). 
Another study showed that maternal plasma 
PFOA levels correlated with reduced birth 
weight among 1,400 women and their infants. 
PFOS and PFOA levels in maternal plasma 
were, on average, 35.3 and 5.6 ng/mL, respec-
tively (Fei et al. 2007).
Given that few reports have actually sug-
gested a correlation between prenatal non-
occupational PFOS and PFOA exposure 
and reduced fetal growth, further research is 
needed to clarify this potential relationship. 
The aim of the present study was to investigate 
the relationship between relatively low levels 
of PFOS and PFOA in maternal serum and 
birth weight and birth size, including length, 
chest circumference, and head circumference.
Materials and Methods
Study population. We performed a prospec-
tive cohort study between July 2002 and 
October 2005 at the Sapporo Toho Hospital 
in Hokkaido, Japan (Hokkaido Study on 
Environment and Children’s Health). 
Study subjects were women who enrolled at 
23–35 weeks of gestation during a routine 
Address correspondence to R. Kishi, Department 
of Public Health, Hokkaido University, Graduate 
School of Medicine, North 15, West 5, Kita-ku, 
Sapporo 060-8638 Japan. Telephone: 81-11-706-
5068. Fax: 81-11-706-7805. E-mail address: rkishi@
med.hokudai.ac.jp
We thank the medical staff at Sapporo Toho 
Hospital and the participants, and the staff at Fukuoka 
Institute of Health and Environmental Sciences.
This study was supported in part by Grants-in-Aid 
for Scientific Research from the Japan Society for 
the Promotion of Science and the Japan Ministry of 
Health, Labour, and Welfare.
The authors declare they have no competing 
  financial interests.
Received 9 May 2008; accepted 4 November 2008.
Correlations between Prenatal Exposure to Perfluorinated Chemicals and 
Reduced Fetal Growth
Noriaki Washino,1 Yasuaki Saijo,2 Seiko Sasaki,1 Shizue Kato,1 Susumu Ban,1 Kanae Konishi,1 Rie Ito,3 
Ayako Nakata,3 Yusuke Iwasaki,3 Koichi Saito,3 Hiroyuki Nakazawa,3 and Reiko Kishi1
1Department of Public Health, Hokkaido University Graduate School of Medicine, Sapporo, Japan; 2Department of Health Science, 
Asahikawa Medical College, Asahikawa, Japan; 3Department of Analytical Chemistry, Faculty of Pharmaceutical Sciences, Hoshi 
University, Tokyo, Japan
ba c K g r O u n d: Perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA) are man-made, 
  ubiquitous, and persistent contaminants in the environment, wildlife, and humans. Although 
recent studies have shown that these chemicals interfere with fetal growth in humans, the results are 
  inconsistent.
Objectives: Our goal was to investigate the correlation between relatively low levels of PFOS and 
PFOA in maternal serum and birth weight and birth size.
Me t h O d s : We conducted a hospital-based prospective cohort study between July 2002 and 
October 2005 in Sapporo, Japan. A total of 428 women and their infants were involved in the 
study. We obtained characteristics of the mothers and infants from self-administered questionnaire 
surveys and from medical records. We analyzed maternal serum samples for PFOS and PFOA by 
liquid chromatography–tandem mass spectrometry (LC/MS/MS).
re s u l t s: After adjusting for confounding factors, PFOS levels negatively correlated with birth 
weight [per log10 unit: β = –148.8 g; 95% confidence interval (CI), –297.0 to –0.5 g]. In addition, 
analyses stratified by sex revealed that PFOS levels negatively correlated with birth weight only in 
female infants (per log10 unit: β = –269.4 g; 95% CI, –465.7 to –73.0 g). However, we observed no 
correlation between PFOA levels and birth weight.
cO n c l u s i O n: Our results indicate that in utero exposure to relatively low levels of PFOS was nega-
tively correlated with birth weight.
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gynecologic checkup and delivered at the 
Sapporo Toho Hospital. All subjects were 
native Japanese and residents of Sapporo or 
surrounding areas. Of 1,796 potentially eli-
gible women, 514 agreed to participate (a 
participation rate of 29%). Among the 514 
pregnant women who composed the initial 
cohort, 10 were excluded because of miscar-
riage, stillbirth, relocation, or voluntary with-
drawal from the study before follow-up. 
The subjects completed a self-adminis-
tered questionnaire survey after the second 
trimester of pregnancy. The questionnaire 
included information related to dietary habits, 
smoking status, alcohol intake, caffeine intake, 
household income, and educational level. We 
obtained information on dietary habits dur-
ing pregnancy, such as intake of eggs, milk 
and its by-products, carbo  hydrates, fish, and 
meat, from responses on the food frequency 
questionnaire, divided into five cate  gories: 
rarely/never, one to two times per month, one 
to two times per week, three to four times per 
week, or every day. In this study, we based 
maternal smoking status on maternal self-
reporting and categorized it into two groups: 
nonsmokers [those who did not smoke 
throughout pregnancy or quit smoking at the 
beginning of pregnancy (first trimester)] and 
smokers (those who continued to smoke dur-
ing pregnancy, which included women who 
quit after the second trimester). 
For estimating alcohol intake, we used 
the modified self-administered questionnaire 
described previously by Nagata et al. (1997). 
We calculated average daily alcohol consump-
tion during pregnancy in grams of ethanol for 
regular drinkers on the basis of beverage type, 
frequency of alcoholic beverage consumption, 
and the amount consumed per occasion dur-
ing pregnancy. The questionnaire contained 
queries on the intake of alcoholic beverages 
popular in Japan, including sake (rice wine), 
shochu (a type of brandy), beer, light beer, 
wine, and other kinds of alcohol drinks (e.g., 
whiskey, brandy, gin, vodka, cocktails, rum). 
Frequency of alcohol intake during pregnancy 
was classified into nine categories: rarely/
never, once per month, two to three times 
per month, once per week, two to three times 
per week, four to six times per week, once per 
day, two to three times per day, or more than 
four times per day. The quantity per occasion 
during pregnancy for sake and shochu was 
classified into four categories: ≤ 1 go, 2 go, 
3 go, and ≥ 4 go (in Japan, the go is the most 
commonly used measure of sake and shochu 
consumption; 1 go of sake and shochu, equiv-
alent to 180 mL, contains approximately 22 g 
and 37 g ethanol, respectively). The quantity 
per occasion during pregnancy for beer and 
light beer was classified into four categories: 
one can of beer or less, one bottled beer, two 
to three bottled beers, four or more bottled 
beers. One can of beer and light beer con-
tains approximately 14 g and 10 g ethanol, 
respectively, and one bottle of beer and light 
beer contains approximately 25 g and 15 g 
ethanol, respectively. The quantity per occa-
sion during pregnancy for wine and the other 
kinds of alcohol drinks was classified into four 
categories: one glass or less, two glasses, three 
glasses, four or more glasses. One glass of wine 
and the other kinds of alcohol drinks contains 
approximately 11 g and 21 g ethanol, respec-
tively. We calculated the amount of ethanol 
consumed per day as the amount consumed 
per occasion multiplied by the ethanol con-
tent for each beverage type multiplied by the 
frequency of intake per day. In the present 
study, we used total alcohol intake from all 
beverages as the “exposure.”
For estimating caffeine intake, we used 
the modified self-administered questionnaire 
described previously by Nagata et al. (1998). 
We calculated average daily caffeine consump-
tion during pregnancy in milligrams of caffeine 
for regular drinkers on the basis of beverage 
type, frequency of caffeinated beverage con-
sumption, and the amount consumed per 
occasion during pregnancy. The questionnaire 
contained queries on the intake of caffeinated 
beverages popular in Japan, including coffee 
[one cup of instant coffee (60 mg caffeine), 
regular coffee (50 mg), decaffeinated coffee 
(0 mg), and canned coffee (50 mg)], tea [one 
cup of black tea (60 mg), oolong tea (30 mg), 
powdered green tea (200 mg), Gyokuro (green 
tea of the highest quality; 100 mg), and other 
kinds of tea such as natural leaf tea, coarse 
green tea, brown rice tea, and roasted green tea 
(30 mg)], one cup of cocoa (5 mg), one glass 
of cola (60 mg), and one bottle of caffeinated 
health drink (50 mg). Frequency of intake 
during pregnancy was divided into five cat-
egories: rarely/never, once or twice per month, 
once or twice per week, three to four times per 
week, or every day. The quantity per occasion 
for caffeinated beverage during pregnancy was 
classified into four categories; one cup (glass 
or bottle) or less, two cups (glasses or bottles), 
three cups (glasses or bottles), and four cups 
or more (glasses or bottles). We calculated 
the caffeine amount consumed per day as the 
amount consumed per occasion multiplied 
by the caffeine content of beverage type mul-
tiplied by the frequency of intake per day. In 
the present study, we used total caffeine intake 
from all beverages as the “exposure.” 
Annual household income based on 
maternal self-reporting was divided into 
five categories: < 3 million yen, 3–5 million 
yen, 5–7 million yen, 7–10 million yen, or 
≥ 10 million yen. Maternal educational level 
based on maternal self-reporting was divided 
into four categories: 9 years, 10–12 years, 
13–16 years, or ≥ 17 years. We obtained 
the information for exclusion criteria and 
potential confounders of the mothers and 
their infants—prepregnancy body mass index 
(BMI), pregnancy complications, gestational 
age, infant sex, parity, infant disease, birth 
weight, and birth size—from medical records 
written by gynecologists. This study was con-
ducted with written informed consent from 
all subjects and was approved by the institu-
tional ethical board for epidemiologic studies 
at the Hokkaido University Graduate School 
of Medicine.
Exposure assessment. A 40-mL blood sam-
ple was taken from the maternal peripheral 
vein after the second trimester of pregnancy. 
When this was not possible because of anemia 
of the mother, we took a blood sample after 
delivery. All samples were stored at –80°C 
until analysis. The analytical detection method 
used is the variation of a method published 
previously (Nakata et al. 2005a, 2005b), and 
the methods for developing this analytical 
approach are also available elsewhere (Inoue 
et al. 2004a, 2004b).
We obtained PFOS [molecular weight 
(MW), 538.23 Da; 98% purity] and PFOA 
(MW, 414.07 Da; > 90% purity) from Fluka 
Chemie AG (Buchs, Switzerland). We pur-
chased perfluoroheptanoic acid (PFHpA, 99%), 
which we used as an internal standard, from 
Sigma Chemical Co. (St. Louis, MO, USA). 
We purchased acetonitrile and methanol for 
high-performance liquid chromatography and 
analytical-grade ammonium acetate and acetic 
acid from Wako Pure Chemical Industries, Ltd. 
(Osaka, Japan). The water purification system 
was a Milli-Q gradient A 10 (185 nm ultra-
violet, ion exchange, and filtration) equipped 
with an EDS polisher (activated carbon filtra-
tion) (Millipore, Bedford, MA, USA).
Instrumentation and analytical conditions 
for column-switching liquid chromatography– 
tandem mass spectrometry coupled with 
solid-phase extraction. We performed liquid 
chromatography–tandem mass spectrometry 
(LC/MS/MS) with a Waters Quattro micro 
system (Nihon Waters KK, Tokyo, Japan). 
Separation was achieved on an Inertsil ODS-3 
column (2.1 × 50 mm, 5 µm; GL Sciences 
Inc., Tokyo, Japan) equipped with a Mightysil 
RP-18 GP precolumn (2.0 × 5 mm, 5 µm; 
Kanto Chemical Inc., Osaka, Japan). The 
column oven was maintained at 40°C. The 
column-switching LC/MS/MS was coupled 
with an online extraction system consisting of 
the LC/MS/MS combined with an LC pump 
(LC-10ADvp pump; Shimadzu, Kyoto, Japan) 
and a Waters Oasis HLB extraction column 
(2.1 × 20 mm, 25 µm). After we injected a 
50-µL sample with an autosampler, we loaded 
it onto the extraction column by flowing 
50 mM acetate buffer (pH = 4.7):methanol 
(90:10, vol/vol) at a flow rate of 1.0 mL/min. 
The valve was switched 5 min after sample 
injection. We eluted the sample through a Washino et al.
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back-flashing extraction column to the ana-
lytical column and introduced it into the 
MS/MS apparatus. We carried out separa-
tion using a mobile phase of 1.0 mM ammo-
nium acetate/acetonitrile (vol/vol) at a flow 
rate of 0.2 mL/min. The gradient profile was 
as follows: linear increase from 45% to 85% 
acetonitrile solution for 5–12 min, then hold 
at 85% for 3 min. The conditions for MS/
MS were as follows: Desolvation and source 
temperatures were set at 350°C and 100°C, 
respectively, and the capillary was held at a 
potential of 600 V relative to the counterelec-
trode in the negative-ion mode for all com-
pounds. Cone and desolvation gas flow rates 
were 50 and 350 L/hr, respectively. Cone and 
collision voltages were 60 and 65 V for PFOS, 
30 and 18 V for PFOA, and 28 and 18 V 
for PFHpA, respectively. When we tested the 
recoveries using human plasma samples, the 
recoveries for spiked 5 and 50 ng/mL PFOS 
were 99.3% [coefficient of variation (CV), 
3.0%] and 97.5% (CV, 6.3%), respectively 
(n = 6), and the recoveries for spiked 1 and 
10 ng/mL PFOA were 100.0% (CV, 8.9%) 
and 97.3% (CV, 4.8%), respectively (Nakata 
et al. 2005a, 2005b). In addition, we further 
verified reliability of our method through par-
ticipation in the First International Laboratory 
Calibration Study coordinated by Animal 
Sciences Group-The Netherlands Institute for 
Fisheries Research (ASG-RIVO) and Örebro 
University (Lindström et al. 2005). Our labo-
ratory reported acceptable results. Thus, we 
judged our results to be accurate and precise.
Sample preparation. We mixed human 
plasma samples (0.1 mL) with 0.2 mL inter-
nal standard solution containing acetonitrile, 
centrifuged the mix at 1,450 × g for 10 min, 
and transferred the supernatant to a polypro-
pylene tube. We subjected the aliquot of the 
filtered sample solution to column-switching 
LC/MS/MS.
As a result of loss to follow-up, lack of 
serum specimen, and laboratory capacity, we 
ultimately measured the concentrations of 
perfluorinated chemicals in 447 maternal sera 
samples. We measured the concentrations 
of 7 polychlorinated dibenzo-p-dioxins, 10 
polychlorinated dibenzofurans, and 4 non-
ortho-polychlorinated biphenyls (PCBs) using 
high-resolution gas chromatography/high 
resolution mass spectrometry (HRGC/
HRMS) equipped with a solvent cut large-
volume (SCLV) injection system (SGE Ltd., 
Victoria, Australia) and we also measured 
8 mono-ortho-PCBs and 58 non-dioxin-like 
PCB congeners in maternal blood (n = 370) 
using HRGC/HRMS at Fukuoka Institute of 
Health and Environmental Sciences. The ana-
lytical method is available elsewhere (Todaka 
et al. 2007, 2008).
Data analysis. For analysis of maternal 
PFOS and PFOA levels and correlations with 
birth weight and birth size, we excluded subjects 
Table 1. Maternal serum PFOS and PFOA concentrations [median (interquartile range)] in relation to 
maternal and infant characteristics (n = 428).
Characteristic  No. (%)  PFOS  PFOA 
Maternal characteristics 
Age (years)*  30.5 ± 4.8a  r = –0.173  r = –0.095
Educational level (years) 
  ≤ 12  192 (44.9)  4.9 (3.6–6.6)  1.2 (0.8–1.8)
  ≥ 13  236 (55.1)  5.5 (3.4–7.4)  1.3 (0.8–1.8)
Annual household income (million yen)b 
  < 3  86 (20.2)  5.5 (3.8–7.8)  1.4 (0.8–2.0)
  3–5  210 (49.4)  5.0 (3.4–6.8)  1.2 (0.8–1.6)
  5–7  86 (20.2)  5.5 (3.5–7.0)  1.3 (0.9–1.8)
  ≥ 7  43 (10.1)  5.8 (3.4–7.2)  1.5 (0.9–2.4)
Maternal smoking status during pregnancy* 
  Nonsmoking  334 (78.0)  5.3 (3.7–7.3)  1.3 (0.8–1.8)
  Smoking  94 (22.0)  4.7 (3.0–6.5)  1.2 (0.8–1.6)
Alcohol intake during pregnancy 
  No  299 (69.9)  5.2 (3.5–6.9)  1.3 (0.8–1.8)
  Yes  129 (30.1)  5.3 (3.4–7.3)  1.3 (0.8–1.8)
Alcohol intake among drinkers during
  pregnancy (g/day)  1.4 (0.4–152.0)c  r = 0.024  r = –0.033
Caffeine intake during 
  pregnancy (mg/day)**  124.0 (2.0–1242.5)c  r = –0.064  r = –0.131
Prepregnancy BMI (kg/m2)  21.1 ± 3.1a  r = –0.079  r = –0.091
Blood sampling period*,** 
  During pregnancy  310 (72.4)  5.6 (4.1–7.5)  1.4 (0.9–2.0)
  After delivery  118 (27.6)  3.8 (2.5–5.6)  1.0 (0.6–1.5)
Type of delivery* 
  Vaginal  343 (80.1)  5.4 (3.8–7.3)  1.3 (0.8–1.8)
  Cesarean section  85 (19.9)  4.3 (3.0–6.5)  1.2 (0.8–1.6)
Infant characteristics 
Gestational age (days)*,**  275.5 ± 9.9a  r = 0.130  r = 0.107
Sex** 
  Male  198 (46.3)  5.2 (3.7–7.0)  1.4 (0.9–1.9)
  Female  230 (53.7)  5.2 (3.2–7.1)  1.2 (0.8–1.7)
Parity*,** 
  0  202 (47.2)  5.8 (4.0–8.0)  1.6 (1.2–2.1)
  ≥ 1  226 (52.8)  4.8 (3.0–6.4)  0.9 (0.6–1.4)
aMean ± SD. bData for annual income were missing for three mothers. cMedian (minimum–maximum).
*,**Statistically significant differences (p < 0.05) using the Spearman’s correlation test, Mann–Whitney U-test, and 
Kruskal–Wallis test for PFOS (*) for PFOA (**).
Table 2. Birth outcomes for study end points (n = 428).
End point  Mean ± SD
Birth weight (g)  3058.1 ± 376.3
Length (cm)  48.1 ± 1.8
Chest circumference (cm)  31.4 ± 1.6
Head circumference (cm)  33.2 ± 1.3
Table 3. Concentrations of PFOS and PFOA (ng/mL) in maternal serum (n = 428). 
  Detection  Percentile  Geometric
  limita  ND (%)  Mean  Minimum  25th  50th  75th  Maximum  mean
PFOS  0.5  0 (0)  5.6  1.3  3.4  5.2  7.0  16.2  4.9
PFOA  0.5  31 (7.2)  1.4  ND  0.8  1.3  1.8  5.3  1.2
ND, nondetectable. 
aFor subjects with a level below the detection limit, we used a value equal to half the detection limit. 
Figure 1. Box and whisker plots of PFOS and PFOA 
concentrations in maternal serum. Horizontal lines 
inside boxes indicate the median, boxes represent 
the interquartile range, whiskers indicate the most 
extreme data points < 1.5 times the interquartile 
range from the ends of the box, and circles indi-
cate outliers. Subjects with PFOA level < 0.5 ng/mL 
are noted as 0.25 ng/mL.
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having maternal pregnancy-induced hyperten-
sion, diabetes mellitus, fetal heart failure, and 
twins. Ultimately, we included in the analy-
sis 428 mother–infant pairs for whom we had 
measured PFOS and PFOA concentrations.
We analyzed correlations between PFOS 
and PFOA concentrations and characteris-
tics of mothers and infants by the Spearman 
correlation test, Mann–Whitney U-test, 
and Kruskal–Wallis test and analyzed corre-
lations between birth weight and birth size 
and characteristics of mothers and infants 
by the Student’s t-test and Pearson’s corre-
lation test. Finally, we performed multiple 
regression analyses to determine correlations 
between PFOS and PFOA levels and birth 
weight and birth size. Because of the skewed 
distributions, we treated the levels of PFOS 
and PFOA in maternal serum as a continu-
ous variable on a log10 scale. For subjects with 
a level less than the detection limit, we used 
a value equal to half of the detection limit. 
The fully adjusted model used multiple regres-
sion analysis adjusted for maternal age, mater-
nal educational level, smoking status during 
pregnancy, maternal BMI, parity, infant sex, 
and gestational age. For head circumference, 
we included delivery mode (vaginal deliv-
ery vs. cesarean section) in the fully adjusted 
model as a potential predictor of head cir-
cumference. When we examined the levels of 
PFOS and PFOA in samples taken at differ-
ent times (during pregnancy and after deliv-
ery) by the Mann–Whitney U-test, we found 
significant differences in the levels of PFOS 
(p < 0.001) and PFOA (p < 0.001). Thus, 
we also adjusted the blood sampling time in 
the fully adjusted model. We performed all 
statistical analyses using SPSS for Windows, 
version 13.0J (Japanese version; SPSS, Inc., 
Chicago, IL, USA). Results were considered 
statistically   significant if p < 0.05.
Results
Table 1 shows maternal serum PFOS and 
PFOA concentrations in relation to char-
acteristics of mothers and infants. In total, 
we included 428 mother–infant pairs in the 
study. The mean (± SD) maternal age was 
30.5 ± 4.8 years. Maternal educational level 
was divided into two categories, ≤ 12 years and 
≥ 13 years, because the numbers of subjects in 
the “9 years” and “≥ 17 years” categories were 
only 11 (2.6%) and 6 (1.4%), respectively. 
The numbers of subjects in the two categories, 
≤ 12 years and ≥ 13 years, were 192 (44.9%) 
and 236 (55.1%), respectively. For annual 
income, the number of subjects in the “≥ 10 
million yen” category was only 5 (1.2%), so 
we included these in the “≥ 7 million yen” 
category. The numbers of subjects in the four 
categories, < 3 million yen, 3–5 million yen, 
5–7 million yen, and ≥ 7 million yen, were 
86 (20.2%), 210 (49.4%), 86 (20.2%), and 
43 (10.1%), respectively. The number of sub-
jects in the category “maternal smoking dur-
ing pregnancy,” which included women who 
quit smoking after the second trimester, was 
94 (22.0%), and the number in the category 
“maternal nonsmoking during pregnancy,” 
which included women who quit in the first 
trimester, was 334 (78.0%). The numbers 
of subjects in the category “blood sampling 
during pregnancy” and “blood sampling after 
delivery” were 310 (72.4%) and 118 (27.6%), 
respectively. There were 198 male infants 
(46.3%) and 230 female infants (53.7%). 
The mean (± SD) gestational age was 275.5 
± 9.9 days. We observed statistically signifi-
cant differences (p < 0.05) in median PFOS 
concentrations by age, smoking status, blood 
sampling period, type of delivery, gestational 
age, and parity, and we observed differences 
in median PFOA concentrations by caffeine 
intake, blood sampling period, gestational age, 
infant sex, and parity. Table 2 shows birth 
outcomes of study subjects. The mean (± SD) 
birth weight was 3058.1 ± 376.3 g.
Table 3 presents PFOS and PFOA con-
centrations included in the analysis (n = 428), 
and Figure 1 shows box and whisker plots 
of PFOS and PFOA concentrations. Both 
detection limits were 0.5 ng/mL. We detected 
PFOS in every maternal serum sample and 
PFOA in 92.8% of samples. PFOA level 
was below the detection limit in 31 (7.2%) 
samples. Concentrations ranged from 1.3 
to 16.2 ng/mL for PFOS and from below 
the detection limit to 5.3 ng/mL for PFOA. 
Concentrations of PFOS and PFOA in mater-
nal serum were highly correlated (Spearman 
rank correlation coefficient, 0.242; p < 0.01).
Table 4 presents relationships between 
birth weight and birth size and subject char-
acteristics; we compared the data using the 
Student’s t-test and Pearson’s correlation test. 
The mean birth weight, chest circumference, 
and head circumference were significantly 
lower in the smoker group compared with 
nonsmoker group (p < 0.05). Gestational 
age (days) had the greatest positive impact 
on infant birth weight and birth size (all 
p < 0.001). Maternal prepregnancy BMI posi-
tively correlated with birth weight (p < 0.05). 
Table 4. Relationship between birth weight and birth size and subject characteristics [mean ± SD (n = 428)]. 
            Chest    Head
Characteristic  No.  Birth weight (g)  p-Value  Length (cm)  p-Value  circumference (cm)  p-Value   circumference (cm)  p-Value
Maternal characteristics 
Age (years)    r = –0.041  0.397  r = –0.022  0.646  r = –0.021  0.665  r = 0.051  0.289
Educational level (years) 
  ≤ 12  192  3028.4 ± 362.0  0.141  47.9 ± 1.8  0.095  31.3 ± 1.5  0.172  33.1 ± 1.2  0.159
  ≥ 13  236  3082.3 ± 386.6    48.2 ± 1.8    31.5 ± 1.7    33.3 ± 1.3
Annual household income (million yen) 
  < 5  296  3071.3 ± 366.9  0.360  48.1 ± 1.7  0.550  31.4 ± 1.6  0.664  33.2 ± 1.3  0.982
  ≥ 5  129  3034.9 ± 398.0    48.0 ± 1.9    31.4 ± 1.7    33.2 ± 1.3
Smoking status during pregnancy 
  Nonsmoker  334  3080.0 ± 384.4  0.023*  48.1 ± 1.8  0.162  31.5 ± 1.6  0.036*  33.3 ± 1.3  0.023*
  Smoker  94  2980.5 ± 336.4    47.9 ± 1.6    31.1 ± 1.4    33.0 ± 1.1
Alcohol intake among drinkers 
  during pregnancy (g/day)    r = 0.027  0.760  r = 0.022  0.809  r = 0.057  0.518  r = 0.013  0.883
Caffeine intake during 
  pregnancy (mg/day)    r = –0.057  0.237  r = –0.064  0.185  r = –0.041  0.400  r = –0.011  0.828
Prepregnancy BMI    r = 0.104  0.032*  r = 0.043  0.376  r = 0.058  0.229  r = 0.070  0.151
Infant characteristics 
Sex 
  Male  198  3095.8 ± 378.7  0.055  48.4 ± 1.8  0.001*  31.5 ± 1.5  0.255  33.6 ± 1.3  < 0.001*
  Female  230  3025.8 ± 372.0    47.8 ± 1.7    31.3 ± 1.7    33.0 ± 1.2
Gestational age (days)    r = 0.500  < 0.001*  r = 0.464  < 0.001*  r = 0.465  < 0.001*  r = 0.218  < 0.001*
Parity 
  0  202  3031.4 ± 381.3  0.165  48.1 ± 1.7  0.854  31.3 ± 1.7  0.212  33.1 ± 1.3  0.019*
  ≥ 1  226  3082.0 ± 371.0    48.1 ± 1.8    31.5 ± 1.5    33.4 ± 1.3
*Statistically significant, p-value < 0.05, Student’s t-test, Pearson’s correlation test. Washino et al.
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Length and head circumference in male 
infants were significantly greater compared 
with female infants (p = 0.001 and p < 0.001, 
respectively). Head circumference for first 
infants was significantly smaller than for sub-
sequent infants (p < 0.05).
Table 5 shows univariate and multivariate 
regression model results for birth weight and 
birth size on log10-transformed PFOS and 
PFOA concentrations. Multivariate models 
of birth weight and birth size are adjusted 
for gestational age only or fully adjusted; the 
fully adjusted model includes risk factors cor-
related with birth weight and birth size at 
p-values < 0.05, risk factors known to be cor-
related with birth weight and birth size from 
previous reports, and blood sampling period 
(i.e., maternal age, maternal educational level, 
maternal smoking status during pregnancy, 
maternal BMI, parity, infant sex, gestational 
age, blood sampling period; delivery mode 
was included for head circumference). In the 
crude model, we found no significant cor-
relations between PFOS and PFOA levels 
and birth weight and birth size. In the model 
adjusted only for gestational age, a log10-unit 
increase in PFOS and PFOA levels correlated 
with a decrease in mean birth weight of 148.7 
g [95% confidence interval (CI), 291.2 to 6.2 
g] for PFOS and 119.1 g (95% CI, 228.8 to 
9.3 g) for PFOA. Further adjustment for par-
ity resulted in a loss of the significant negative 
correlation between PFOA levels and birth 
weight, so the fully adjusted model showed 
no significant negative correlation between 
PFOA levels and birth weight. In contrast, 
a log10-unit increase in PFOS levels corre-
lated with a decrease in mean birth weight of 
148.8 g (95% CI, 297.0 to 0.5 g) for PFOS 
in the fully adjusted model. Figure 2 plots 
the predicted values from selected regression 
models in male and female infants across 
the full range of log10-transformed maternal 
PFOS concentrations. 
Table 6 shows the results of multiple 
regression analyses between maternal PFOS 
and PFOA levels and birth weight and birth 
size in male infants. In the model adjusted 
only for gestational age, a log10-unit increase 
in PFOA levels correlated with a decrease 
in mean birth weight of 166.4 g (95% CI, 
328.9 to 4.0 g). Further adjustment for par-
ity resulted in a loss of significant negative 
correlation between PFOA levels and birth 
weight in male infants, so the fully adjusted 
model shows no significant negative correla-
tion between PFOA levels and birth weight in 
male infants. In the crude model, a log10-unit 
increase in PFOS levels correlated with an 
increase in mean length of 1.230 cm (95% 
CI, 0.075 to 2.386 cm). However, after 
adjustment for gestational age, the significant 
positive correlation disappeared.
Table 7 shows the results of multiple 
regression analyses between maternal PFOS 
and PFOA levels and birth weight and birth 
size in female infants. In the crude model, 
we observed no significant correlations 
between PFOS levels and birth weight. In 
the model adjusted only for gestational age, a 
log10-unit increase in PFOS levels correlated 
with a decrease in the mean birth weight of 
237.1 g (95% CI, 425.0 to 49.1 g). In the 
fully adjusted model, a log10-unit increase 
in PFOS levels correlated with a decrease 
in mean birth weight of 269.4 g (95% CI, 
465.7 to 73.0 g). Figure 3 plots the pre-
dicted values from selected regression mod-
els in female infants across the full range of 
log10-  transformed PFOS concentrations. 
We observed marginally significant nega-
tive correlations between PFOS levels and 
length and chest circumference in the fully 
adjusted model.
Among the subjects analyzed in this study 
(n = 428), we measured the levels of total 
dioxins in maternal blood [sum of 7 polychlo-
rinated dibenzo-p-dioxins, 10 polychlorinated 
dibenzofurans, and 12 dioxin-like PCBs (four 
non-ortho PCBs and eight mono-ortho PCBs)] 
(n = 318) and the levels of total PCBs (sum 
of 70 PCB congeners (58 non-dioxin-like 
PCB congeners and 12 dioxin-like PCBs) in 
maternal blood (n = 318) (data not shown). 
Total dioxins levels positively correlated with 
PFOS and PFOA levels [Spearman rank cor-
relation coefficients, 0.149 (p = 0.008) and 
0.162 (p = 0.004), respectively]. Furthermore, 
total PCB levels positively correlated with 
PFOA levels (Spearman rank correlation coef-
ficient, 0.136; p = 0.015) but not with PFOS 
levels (Spearman rank correlation coefficient, 
0.089; p = 0.111). However, the fully adjusted 
regression coefficients between PFOS and 
PFOA levels and birth weight also changed 
little when we adjusted for total dioxins and 
total PCB levels (data not shown).
Discussion
Our results indicate that in utero exposure to 
relatively low levels of PFOS negatively cor-
related with birth weight, but PFOA levels did 
not correlate with birth weight. Two previous 
studies suggested that prenatal nonoccupa-
tional PFOS and PFOA exposure correlated 
with reduced fetal growth (Apelberg et al. 
2007b; Fei et al. 2007). One study showed a 
significant negative correlation between mater-
nal plasma PFOA levels, but not PFOS lev-
els, and birth weight in a prospective cohort 
study among 1,400 women and their infants 
Table 5. Regression coefficients (95% CI) between PFOS and PFOA concentrations (ng/mL) in maternal 
serum and birth weight and birth size (n = 428).
  Partial regression    Partial regression 
Dependent variable  coefficient of log10 PFOSa  p-Value  coefficient of log10 PFOAa  p-Value
Birth weight (g) 
  Crude  –15.1 (–178.3 to 148.1)  0.856  –39.8 (–166.1 to 86.4)  0.536
  Adjusted for gestational age  –148.7 (–291.2 to –6.2)  0.041*  –119.1 (–228.8 to –9.3)  0.034*
  Fully adjustedb  –148.8 (–297.0 to –0.5)  0.049*  –75.1 (–191.8 to 41.6)  0.207
Length (cm) 
  Crude  0.488 (–0.283 to 1.258)  0.214  0.216 (–0.381 to 0.813)  0.478
  Adjusted for gestational age  –0.086 (–0.779 to 0.607)  0.807  –0.127 (–0.660 to 0.407)  0.641
  Fully adjustedb  –0.183 (–0.912 to 0.546)  0.622  –0.140 (–0.712 to 0.432)  0.631
Chest circumference (cm) 
  Crude  0.138 (–0.553 to 0.829)  0.696  –0.067 (–0.602 to 0.468)  0.806
  Adjusted for gestational age  –0.384 (–1.003 to 0.235)  0.224  –0.378 (–0.854 to 0.099)  0.120
  Fully adjustedb  –0.389 (–1.046 to 0.268)  0.245  –0.194 (–0.710 to 0.322)  0.460
Head circumference (cm) 
  Crude  –0.077 (–0.641 to 0.487)  0.788  –0.083 (–0.519 to 0.354)  0.710
  Adjusted for gestational age  –0.280 (–0.836 to 0.277)  0.324  –0.202 (–0.631 to 0.227)  0.355
  Fully adjustedb  –0.204 (–0.781 to 0.372)  0.486  –0.051 (–0.503 to 0.400)  0.823
aBecause PFOS and PFOA levels were log10-transformed, partial regression coefficients represent the expected change 
in dependent variables as a result of a 10-fold change in PFOS and PFOA levels. bAdjusted for maternal age, maternal 
educational level, smoking status during pregnancy, maternal BMI, parity, infant sex, gestational age, and blood sampling 
period. For head circumference, adjusted model also includes delivery mode (cesarean section/vaginal). *Statistically 
significant, p-value < 0.05.
Figure 2. Birth weight in both male and female 
infants and log10 maternal PFOS concentrations, 
before and after adjustment for potential confound-
ers. The black line denotes the predicted fit from 
a simple linear regression model (birth weight = 
3068.6–15.1 log10 PFOS); the gray line denotes the 
predicted fit from the fully adjusted multivariate 
regression model (birth weight = 3127.3–148.8 log10 
PFOS). Table 5 presents corresponding regression 
coefficients. 
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(Fei et al. 2007), and the other study showed 
a negative correlation between cord serum 
PFOS and PFOA levels and birth weight in 
a cross-sectional study among 293 women 
and their infants (Apelberg et al. 2007b). Our 
results are inconsistent with these two reports. 
Differences in blood sample types, sampling 
periods, and laboratories may have affected 
the results, but these differences are unlikely 
to account entirely for the inconsistency of the 
findings. Differences in confounder adjust-
ment could be an alternative explanation. Fei 
et al. (2007) adjusted for quadratic gestational 
age, and Apelberg et al. (2007b) adjusted for 
maternal height and net weight gain during 
pregnancy, both of which are confounding 
factors not considered in our fully adjusted 
model. However, our regression coefficients 
did not change markedly when we adjusted 
for these variables. On the other hand, dif-
ferences in PFOS and PFOA concentrations 
also could be an alternative explanation. Fei 
et al. (2007) reported that PFOS and PFOA 
levels in maternal plasma were, on average, 
35.3 (range, 6.4 to 106.7 ng/mL) and 5.6 
ng/mL (range, < 1.0 to 41.5 ng/mL), respec-
tively. Serum-to-plasma ratios for PFOS and 
PFOA have been reported as 1:1 (Ehresman 
et al. 2007). Our cohort study showed average 
PFOS and PFOA levels in maternal serum 
to be 5.6 ng/mL (range, 1.3 to 16.2 ng/mL) 
and 1.4 ng/mL (range, < 0.5 to 5.3 ng/mL), 
respectively. Although the levels of PFOS and 
PFOA measured in our cohort are lower, we 
observed a negative correlation between only 
PFOS levels and birth weight. Apelberg et al. 
(2007b) reported that the median cord serum 
PFOS and PFOA levels were 5 ng/mL (range, 
< 0.2 to 34.8 ng/mL) and 1.6 ng/mL (range, 
0.3 to 7.1 ng/mL), respectively. The mean 
ratio of PFOS and PFOA concentrations in 
maternal plasma to that in cord plasma has 
been reported as 0.60 and 1.26, respectively 
(Midasch et al. 2007). Additionally, our pre-
vious study showed a mean ratio of 0.32 for 
PFOS concentrations in maternal serum to 
that in cord serum (Inoue et al. 2004a). In our 
present cohort study, we determined median 
levels of PFOS and PFOA in maternal serum 
to be 5.2 ng/mL (range, 1.3 to 16.2 ng/mL) 
and 1.3 ng/mL (range, < 0.5 to 5.3 ng/mL), 
respectively. Our PFOS levels might be lower 
and PFOA levels might be nearly the same as 
those reported by Apelberg et al. (2007b), but 
we did not find a correlation between PFOA 
levels and reduced birth weight. We cannot 
fully explain the inconsistencies between our 
results and the two previous reports with 
respect to differences in PFOS and PFOA con-
centrations. At present, we are currently estab-
lishing a large multihospital-based birth cohort 
in Hokkaido prefecture. Using data from this 
large cohort, we plan to investigate the rela-
tionship between perfluorinated chemicals and 
reduced birth weight with a larger number of 
mother–infant pairs in a further study.
PFOS and PFOA levels in our study 
samples from residents of Sapporo City, 
Hokkaido, Japan, were relatively lower com-
pared with studies in Europe, United States, 
and other domestic areas in Japan (Butenhoff 
et al. 2006; Calafat et al. 2007; Harada et al. 
2007; Kannan et al. 2004; Lau et al. 2007; 
Midasch et al. 2006). Despite relatively lower 
Table 6. Regression coefficients (95% CI) between PFOS and PFOA concentrations (ng/mL) in maternal 
serum and birth weight and birth size in male infants (n = 198).
  Partial regression     Partial regression
Dependent variable  coefficient of log10 PFOSa  p-Value   coefficient of log10 PFOAa  p-Value
Birth weight (g) 
  Crude  61.7 (–184.8 to 308.2)  0.622  –66.4 (–254.0 to 121.3)  0.486
  Adjusted for gestational age  –68.7 (–284.1 to 146.7)  0.530  –166.4 (–328.9 to –4.0)  0.045*
  Fully adjustedb  12.1 (–217.7 to 242.0)  0.917  –68.1 (–246.2 to 110.0)  0.452
Length (cm) 
  Crude  1.230 (0.075 to 2.386)  0.037*  0.026 (–0.864 to 0.916)  0.954
  Adjusted for gestational age  0.659 (–0.373 to 1.690)  0.209  –0.422 (–1.208 to 0.364)  0.291
  Fully adjustedb  0.802 (–0.337 to 1.942)  0.167  –0.241 (–1.129 to 0.648)  0.594
Chest circumference (cm) 
  Crude  0.511 (–0.445 to 1.468)  0.293  0.035 (–0.695 to 0.766)  0.924
  Adjusted for gestational age  0.013 (–0.827 to 0.852)  0.976  –0.346 (–0.984 to 0.292)  0.286
  Fully adjustedb  0.166 (–0.740 to 1.072)  0.718  –0.014 (–0.717 to 0.690)  0.970
Head circumference (cm) 
  Crude  –0.029 (–0.873 to 0.815)  0.947  –0.378 (–1.018 to 0.263)  0.246
  Adjusted for gestational age  –0.255 (–1.082 to 0.571)  0.543  –0.555 (–1.180 to 0.070)  0.081
  Fully adjustedb  0.166 (–0.306 to 0.638)  0.488  –0.093 (–0.783 to 0.597)  0.791
aBecause PFOS and PFOA levels were log10-transformed, partial regression coefficients represent the expected change 
in dependent variables as a result of a 10-fold change in PFOS and PFOA levels. bAdjusted for maternal age, maternal 
educational level, smoking status during pregnancy, maternal BMI, parity, gestational age, and blood sampling period. 
For head circumference, adjusted model also includes delivery mode (cesarean section/vaginal). *Statistically significant, 
p-value < 0.05.
Table 7. Regression coefficients (95% CI) between PFOS and PFOA concentrations (ng/mL) in maternal 
serum and birth weight and birth size in female infants (n = 230).
  Partial regression     Partial regression
Dependent variable  coefficient of log10 PFOSa  p-Value  coefficient of log10 PFOAa  p-Value
Birth weight (g) 
  Crude  –90.7 (–308.6 to 127.1)  0.413  –35.9 (–207.7 to 136.0)  0.681
  Adjusted for gestational age  –237.1 (–425.0 to –49.1)  0.014*  –107.8 (–256.1 to 40.4)  0.153
  Fully adjustedb  –269.4 (–465.7 to –73.0)  0.007*  –76.7 (–234.7 to 81.3)  0.340
Length (cm) 
  Crude  –0.224 (–1.237 to 0.788)  0.663  0.228 (–0.570 to 1.026)  0.574
  Adjusted for gestational age  –0.855 (–1.752 to 0.042)  0.062  –0.080 (–0.787 to 0.626)  0.823
  Fully adjustedb  –0.936 (–1.894 to 0.022)  0.055  –0.020 (–0.786 to 0.746)  0.959
Chest circumference (cm) 
  Crude  –0.199 (–1.190 to 0.792)  0.693  –0.203 (–0.984 to 0.577)  0.608
  Adjusted for gestational age  –0.774 (–1.670 to 0.121)  0.090  –0.490 (–1.191 to 0.212)  0.170
  Fully adjustedb  –0.843 (–1.797 to 0.112)  0.083  –0.340 (–0.721 to 0.198)  0.263
Head circumference (cm) 
  Crude  –0.227 (–0.957 to 0.504)  0.542  0.018 (–0.557 to 0.594)  0.950
  Adjusted for gestational age  –0.443 (–1.165 to 0.278)  0.227  –0.086 (–0.652 to 0.479)  0.764
  Fully adjustedb  –0.508 (–1.270 to 0.254)  0.191  0.001 (–0.605 to 0.608)  0.997
aBecause PFOS and PFOA levels were log10-transformed, partial regression coefficients represent the expected change 
in dependent variables as a result of a 10-fold change in PFOS and PFOA levels. bAdjusted for maternal age, maternal 
educational level, smoking status during pregnancy, maternal BMI, parity, gestational age, and blood sampling period. 
For head circumference, adjusted model also includes delivery mode (cesarean section/vaginal). *Statistically significant, 
p-value < 0.05.
Figure 3. Birth weight and log10 PFOS concentra-
tions in females, before and after adjustment for 
potential confounders. The black line denotes 
the predicted fit from a simple linear regression 
model (birth weight = 3087.8–90.7 log10 PFOS); 
the gray line denotes the predicted fit from the 
fully adjusted multivariate regression model (birth 
weight = 3163.4–269.4 log10 PFOS). Table 7 presents 
corresponding regression coefficients.
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PFOS levels, we found a negative correlation 
between PFOS levels and birth weight.
One recent occupational study showed no 
correlation between high occupational expo-
sure to PFOS before the end of pregnancy and 
maternally reported birth weight (Grice et al. 
2007). However, that study did not adjust 
for the length of gestation, which affects birth 
weight. Therefore, the inconsistency between 
that study and our study might be due to 
inadequate adjustment for gestational period.
Our results show that female infants may 
be more vulnerable to PFOS than are male 
infants. However, Fei et al. (2007) reported 
no correlation between PFOS levels and birth 
weight in neonates after stratification by sex. 
We were unable to infer a mechanism for 
the sex difference in the toxicity of PFOS. 
It is possible that decreasing the sample size 
by stratifying our groups by sex affected our 
results. Thus, further studies are needed to 
clarify any sex-related affects of in utero PFOS 
exposure on birth weight.
In our study, in utero exposure to PFOS 
negatively correlated with birth weight, which 
is consistent with studies in laboratory ani-
mals (Abbott et al. 2007; Butenhoff et al. 
2004; Grasty et al. 2003, 2005; Lau et al. 
2003, 2006; Luebker et al. 2005a, 2005b; 
Thibodeaux et al. 2003; Wolf et al. 2007). 
We observed an inverse correlation between 
PFOS levels and birth weight, although the 
maternal serum concentrations were orders of 
magnitude lower than those at which devel-
opmental effects have been observed in the 
animal toxicity studies. Luebker et al. (2005b) 
estimated a lower bound of the benchmark 
dose correlated with a 5% change in response 
for PFOS and birth weight in rats of 0.39 
mg/kg/day, equivalent to rat fetal serum con-
centrations of 34,000 ng/mL. Humans might 
be more sensitive to PFOS than are rats and 
mice; this might be attributable partly to dif-
ferences between humans and rats/mice with 
respect to half-life for elimination of PFOS—
the half-life for rats is approximately 100 
days (Johnson et al. 1979), whereas that for 
humans is approximately 5 years (Olsen et al. 
2005). At present, the toxicokinetic data and 
the mechanisms related to PFOS toxicity in 
humans are insufficient to explain the inter-
species differences in sensitivity to PFOS.
Concentrations of PFOS and PFOA 
decreased with increasing parity, which is con-
sistent with two previous reports (Apelberg 
et al. 2007b; Fei et al. 2007). This might be 
attributable to placental transfer of perfluo-
rinated chemicals to the fetus (Inoue et al. 
2004a; Midasch et al. 2007) and transfer to 
the infant through breast-feeding (Kärrman 
et al. 2007; So et al. 2006). PFOS and PFOA 
levels sampled during pregnancy were sig-
nificantly higher than PFOS and PFOA 
levels sampled after delivery. This might 
be attributable to blood volume expansion 
and decreased serum albumin concentra-
tion during pregnancy (Swanson and King 
1983; Thibodeaux et al. 2003), changes in 
perfluorinated chemical disposition and phar-
macokinetics during pregnancy (Frederiksen 
2001), and placental transfer of perfluorinated 
chemicals to the fetus (Inoue et al. 2004a; 
Midasch et al. 2007). In our study, PFOS 
levels decreased with increasing maternal age, 
which is consistent with one report (Fei et al. 
2007), and PFOS levels in smokers are lower 
than in nonsmokers, which is consistent with 
another report (Apelberg et al. 2007b). After 
adjusting parity and blood sampling period 
in multiple regression analysis, the correlation 
between log10-transformed PFOS levels and 
maternal age and smoking status remained 
significant (p = 0.024 and p = 0.007, respec-
tively). However, after adjusting for parity, 
blood sampling period, smoking status during 
pregnancy, and maternal age in a multiple 
regression analysis, the significant correlations 
between log10-transformed PFOS levels and 
type of delivery and gestational age disap-
peared (p = 0.059 and p = 0.317, respectively). 
Thus, the correlations between log10-trans-
formed PFOS levels and type of delivery and 
gestational age might have been confounded 
by parity, blood sampling period, smoking 
status during pregnancy, and maternal age. 
Further, after adjusting parity and blood sam-
pling period in a multiple regression analysis, 
the significant correlations between log10-
transformed PFOA levels and caffeine intake 
and gestational age also disappeared (p = 
0.114 and p = 0.584, respectively). Thus, the 
significant correlations between log10-trans-
formed PFOA levels and caffeine intake and 
gestational age might have been confounded 
by parity and blood sampling period. On the 
other hand, the correlations between log10-
transformed PFOA levels and sex were not 
significant after adjustment for parity and 
blood sampling period (p = 0.071). In addi-
tion, besides the covariates in our final model, 
we evaluated the caffeine intake as a possible 
confounding factor; this adjustment did not 
materially change the fully adjusted regression 
coefficients between PFOS and PFOA levels 
and birth weight (data not shown).
Our study constitutes a prospective cohort 
study, which minimizes recall bias. We col-
lected prenatal information on the mother 
and child, such as disease history, pregnancy 
conditions, and birth weight and birth size, 
from medical records written by gynecologists, 
not from maternally reported information, 
adding data reliability. Besides the covariates 
in our final model, we evaluated the frequency 
of food intake (eggs, milk and its by-products, 
carbohydrates, fish, and meat), season of blood 
sampling, and season of birth as possible con-
founding factors. These adjustments did not 
materially change the fully adjusted regression 
coefficients between PFOS and PFOA levels 
and birth weight (data not shown). This study 
has some limitations. First, our sample size 
was relatively small compared with the study 
by Fei et al. (2007). With a larger sample size, 
the correlations between maternal PFOS lev-
els and chest circumference and length may 
be clearer. Second, selection bias may have 
occurred because we based our study on a 
cohort from one area hospital, which treated 
pregnant women in Sapporo and the sur-
rounding areas. In addition, the participation 
rate in our cohort study is low (29%), which 
also may have caused selection bias. Third, 
anthropometric measurements (length, chest, 
and head circumferences) may have errors due 
to length and chest and head molding.
This study shows a correlation between 
maternal PFOS levels and reduced fetal 
growth. PFOS cannot be degraded by the 
environment, and therefore we must evalu-
ate its potential toxicity in humans, especially 
children. Other than birth weight, animal 
studies have shown effects of PFOS and PFOA 
on numerous organ systems, thyroid function, 
endocrine system, immune function, and con-
genital anomalies (Chang et al. 2008; Luebker 
et al. 2005b; Peden-Adams et al. 2007; Seacat 
et al. 2002; Thibodeaux et al. 2003). Little 
research has been conducted on the toxicity 
of PFOS and PFOA in human fetuses. Thus, 
our future studies will investigate whether 
PFOS and PFOA levels correlate with thyroid 
hormone levels, immune function, and neural 
development in human fetuses and infants.
cO r r e c t i O n
In the third-to-last paragraph, the Spearman 
rank correlation coefficients and p-values 
were incorrect in the manuscript origi-
nally published online; they have been 
corrected here.
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